Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Revance Therapeutics Logo
Revance Therapeutics Growth Score
69
CB Rank
31586
Heat Score
67
Revance is a biotechnology company focusing on aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences.
Acquired by
Crown Laboratories Logo
Crown Laboratories
Founded
obfuscation
PublicPost-IPO Equity Newark, California, United States101-250 www.revance.com
Biotechnology
Health Care
Pharmaceutical
Therapeutics
Overview

Revance Therapeutics
Total Funding
obfuscation
Growth Score
69
Heat Score
67

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score69
-3 pts
in past quarter
Heat Score 67
6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+2 more milestones
See more interactive data and historical milestones on desktop for the best experience

About Revance Therapeutics

CB Rank
31586
Revance is a biotechnology company focusing on aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences.
Acquired by
Crown Laboratories Logo
Crown Laboratories
Founded
obfuscation
PublicPost-IPO Equity Newark, California, United States101-250 www.revance.com
Biotechnology
Health Care
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

  • Photo of Todd Gross
    Todd Gross: Vice President, Biostatistics & Data Management
    Past Role: Kythera Biopharmaceuticals, Vice President, Clinical Development, Biostatistics and Data Management
  • Photo of David A. Hollander
    David A. Hollander: Chief Medical Officer
    Past Role: Aerie Pharmaceuticals, Chief R&D Officer

Details

Sub-Organization of 
Crown Laboratories Logo
Crown Laboratories
Legal Name Revance Therapeutics Inc.
Operating Status Active
Stock Symbol  NASDAQ:RVNC
Company Type For Profit
Founders  Dan Browne, Jacob Waugh, Jeffery Bedard
About the Company

Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia

Biosystems.

Phone Number +1 510 742 3400
Contact Email info@revance.com
Predictions & Insights

Growth Insight

See this Growth Insight
Revance Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

DAXXIFY® (DaxibotulinumtoxinA-lanm) Injection
A botulinum toxin injection for temporary improvement of moderate to severe glabellar lines and treatment of cervical dystonia in adults.
RHA® Collection (RHA® 2, RHA® 3, RHA® 4)
A range of hyaluronic acid dermal fillers for treating dynamic facial wrinkles and folds, including perioral rhytids and nasolabial folds.

Research & Development

Revance Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 17
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 17
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Revance Therapeutics Logo
Post-IPO Equity - Revance Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1

M&A Details

Revance Therapeutics merged with Crown Laboratories for
obfuscation
on
obfuscation
. This deal was done in Cash.
Transaction Name 
Revance Therapeutics acquired by Crown Laboratories Logo
Revance Therapeutics acquired by Crown Laboratories
Acquired by 
Crown Laboratories Logo
Crown Laboratories
Announced Date 
obfuscation
Price 
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 27 Board Members and Advisors 7 Contacts 508

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 31, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

50,332
143.44%
 in past month

IT Spend

$5.5MThis year, Revance Therapeutics is projected to spend $5.5M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Zimperium Logo
Zimperium
100
Threat Actor Logo
Threat Actor
100
Cloud-Native Application Development Logo
Cloud-Native Application Development
100

Actively Used Products

35Revance Therapeutics uses 35 technology products and services including HTML5, Google Compute Engine, and  Adobe Flash, according to G2 Stack.

Active Website Tech Count

52Revance Therapeutics is actively using 52 technologies for its website, according to BuiltWith. These include DNSSEC, Cloudflare CDN, and  Mobile Non Scaleable Content.

Total IP

99The intellectual property of Revance Therapeutics includes 69 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Revance Therapeutics has registered 30 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Revance Therapeutics's headquarters? Revance Therapeutics is located in Newark, California, United States.Who invested in Revance Therapeutics? Revance Therapeutics has 17 investors including Athyrium Capital Management LP and  Cowen Investment Management.When was the last funding round for Revance Therapeutics? Revance Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Revance Therapeutics's competitors? Alternatives and possible competitors to Revance Therapeutics may include Galderma, V/O Med Spa, and  Associates In Plastic Surgery.How much funding has Revance Therapeutics raised to date? Revance Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|